FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 227 filers reported holding FATE THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.97 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $663,111 | -57.0% | 312,788 | -3.4% | 0.00% | – |
Q2 2023 | $1,540,526 | -23.9% | 323,640 | -8.9% | 0.00% | – |
Q1 2023 | $2,024,594 | -44.7% | 355,192 | -2.2% | 0.00% | -100.0% |
Q4 2022 | $3,663,416 | -58.1% | 363,074 | -7.0% | 0.00% | -50.0% |
Q3 2022 | $8,747,000 | +0.7% | 390,269 | +11.3% | 0.00% | 0.0% |
Q2 2022 | $8,686,000 | -36.9% | 350,530 | -1.2% | 0.00% | -33.3% |
Q1 2022 | $13,761,000 | -34.4% | 354,949 | -1.0% | 0.00% | -25.0% |
Q4 2021 | $20,970,000 | +3.1% | 358,395 | +4.4% | 0.00% | 0.0% |
Q3 2021 | $20,349,000 | -28.4% | 343,310 | +4.8% | 0.00% | -20.0% |
Q2 2021 | $28,421,000 | +13.3% | 327,468 | +7.6% | 0.01% | 0.0% |
Q1 2021 | $25,093,000 | -12.5% | 304,340 | -3.5% | 0.01% | -16.7% |
Q4 2020 | $28,663,000 | +126.8% | 315,223 | -0.3% | 0.01% | +100.0% |
Q3 2020 | $12,640,000 | +29.9% | 316,259 | +11.6% | 0.00% | 0.0% |
Q2 2020 | $9,727,000 | +54.5% | 283,485 | -0.0% | 0.00% | +50.0% |
Q1 2020 | $6,297,000 | +34.9% | 283,501 | +18.9% | 0.00% | +100.0% |
Q4 2019 | $4,668,000 | +37.6% | 238,509 | +9.1% | 0.00% | 0.0% |
Q3 2019 | $3,393,000 | -27.9% | 218,516 | -5.7% | 0.00% | 0.0% |
Q2 2019 | $4,703,000 | +6.7% | 231,655 | -7.7% | 0.00% | 0.0% |
Q1 2019 | $4,408,000 | +39.9% | 250,887 | +2.2% | 0.00% | 0.0% |
Q4 2018 | $3,150,000 | -27.5% | 245,512 | -8.0% | 0.00% | 0.0% |
Q3 2018 | $4,345,000 | +31.9% | 266,775 | -8.2% | 0.00% | 0.0% |
Q2 2018 | $3,294,000 | +22.0% | 290,529 | +5.0% | 0.00% | 0.0% |
Q1 2018 | $2,700,000 | +190.0% | 276,690 | +81.4% | 0.00% | – |
Q4 2017 | $931,000 | +53.6% | 152,489 | -0.3% | 0.00% | – |
Q3 2017 | $606,000 | +18.6% | 152,937 | -2.9% | 0.00% | – |
Q2 2017 | $511,000 | +88.6% | 157,546 | +164.7% | 0.00% | – |
Q1 2017 | $271,000 | +84.4% | 59,510 | +1.6% | 0.00% | – |
Q4 2016 | $147,000 | -23.0% | 58,558 | -4.2% | 0.00% | – |
Q3 2016 | $191,000 | +63.2% | 61,130 | -10.7% | 0.00% | – |
Q2 2016 | $117,000 | +2.6% | 68,444 | +7.8% | 0.00% | – |
Q1 2016 | $114,000 | -46.5% | 63,503 | +0.1% | 0.00% | – |
Q4 2015 | $213,000 | -37.0% | 63,428 | 0.0% | 0.00% | – |
Q3 2015 | $338,000 | +25.2% | 63,428 | +51.9% | 0.00% | – |
Q2 2015 | $270,000 | +43.6% | 41,766 | +8.6% | 0.00% | – |
Q1 2015 | $188,000 | -2.6% | 38,443 | 0.0% | 0.00% | – |
Q4 2014 | $193,000 | -1.5% | 38,443 | 0.0% | 0.00% | – |
Q3 2014 | $196,000 | -59.5% | 38,443 | -50.0% | 0.00% | – |
Q2 2014 | $484,000 | +29.4% | 76,886 | +100.2% | 0.00% | – |
Q1 2014 | $374,000 | – | 38,400 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |